**BMJ Open**

**Effect of computerised, knowledge-based, clinical decision support systems on patient-reported and clinical outcomes of patients with chronic disease managed in primary care settings: a systematic review**

Marie line El Asmar,1 Kanika I Dharmayat,2 Antonio J Vallejo-Vaz,3,4,5 Ryan Irwin,6 Nikolaos Mastellos7

**ABSTRACT**

**Objectives** Chronic diseases are the leading cause of disability globally. Most chronic disease management occurs in primary care with outcomes varying across primary care providers. Computerised decision support systems (CDSS) have been shown to positively affect clinician behaviour by improving adherence to clinical guidelines. This study provides a summary of the available evidence on the effect of CDSS embedded in electronic health records on patient-reported and clinical outcomes of adult patients with chronic disease managed in primary care.

**Design and eligibility criteria** Systematic review, including randomised controlled trials (RCTs), cluster RCTs, quasi-RCTs, interrupted time series and controlled before-and-after studies, assessing the effect of CDSS (vs usual care) on patient-reported or clinical outcomes of adult patients with selected common chronic diseases (asthma, chronic obstructive pulmonary disease, heart failure, myocardial ischaemia, hypertension, diabetes mellitus, hyperlipidaemia, arthritis and osteoporosis) managed in primary care.

**Data sources** Medline, Embase, CENTRAL, Scopus, Health Management Information Consortium and trial register clinicaltrials.gov were searched from inception to 24 June 2020.

**Data extraction and synthesis** Screening, data extraction and quality assessment were performed by two reviewers independently. The Cochrane risk of bias tool was used for quality appraisal.

**Results** From 5430 articles, 8 studies met the inclusion criteria. Studies were heterogeneous in population characteristics, intervention components and outcome measurements and focused on diabetes, asthma, hyperlipidaemia and hypertension. Most outcomes were clinical with one study reporting on patient-reported outcomes. Quality of the evidence was impacted by methodological biases of studies.

**Conclusions** There is inconclusive evidence in support of CDSS. A firm inference on the intervention effect was not possible due to methodological biases and study heterogeneity. Further research is needed to provide evidence on the intervention effect and the interplay between healthcare setting features, CDSS characteristics and implementation processes.

**PROSPERO registration number** CRD42020218184.

**INTRODUCTION**

Non-communicable chronic diseases are the leading cause of disability and mortality worldwide, affecting one in three adults globally.24 Rising healthcare expenditure because of chronic disease prevalence has led to an ever-growing demand for effective primary care services for the long-term management of chronic conditions.24 Considering that
health systems have mainly adapted to providing periodic care for acute problems, an even greater need to achieve efficient, comprehensive and coordinated long-term care persists. Models such as the chronic care model have been proposed to improve the quality of care in chronic care systems. This model recommends ‘decision support’ as one of six applicable changes in primary care settings that promote better patient outcomes, if successfully implemented. Within this and other models of primary care and chronic condition management, clinicians are encouraged to provide patient care according to evidence-based clinical practice guidelines (CPGs) to support improved patient outcomes. Given the frequent updates to CPGs resulting from rapid advancements in medical knowledge, a major challenge is the maintenance of clinicians’ knowledge of evidence-based CPGs. Consequently, clinicians’ adherence to CPGs may be variable and frequently insufficient, which may result in suboptimal disease management outcomes.

Clinical decision support is an umbrella term that includes various care structures, processes and tools. Clinical decision support systems (CDSS) range from non-computerised to computerised systems and basic to advanced systems. Currently, most attention is driven toward computerised advanced CDSS, which perform complex decision-making functions from electronic health record (EHR) patient data. Such systems are termed knowledge-based, as they use software algorithms to generate actionable patient-specific outputs in the form of recommendations to the practitioner using conditional (IF–THEN) rule statements derived from CPGs. They also differ in their technical and clinical interface, whether passive (providing user-initiated prompts to generate clinical advice, eg, by clicking buttons) or active (automatic system-initiated prompts). CDSS also differ in system–user communication, which could be of consulting nature (ie, provide appropriate ‘next-steps’ clinical recommendations) or of critiquing nature (verify decisions taken by practitioners). Given the differences in interfaces, the scope of this review includes computerised, knowledge-based CDSS embedded in EHRs that are of either passive or active, consulting or critiquing, nature.

Although CDSS are ubiquitous, few have been successfully adopted. Previous reviews appraised the efficacy of different types of CDSS in primary care, presenting a greater consensus on the useful role of CDSS on practitioner-related outcomes such as guideline adherence. However, the impact of CDSS on patient outcomes remains largely uncertain. Bryan et al demonstrated a positive association between the use of CDSS in primary care and patient outcomes. However, a need to further evaluate the effect of CDSS on patient outcomes was identified, particularly in primary care and specifically for chronic disease management. The novel focus of this review is the combined focus on the effect of computerised, knowledge-based, CDSS and their effect on patient-reported and clinical outcomes of patients and with chronic disease and managed in primary care settings. This particular focus was chosen to inform more specific and efficacious implementation strategies in primary care management of chronic disease and attract the industry’s consideration of CDSS use in primary care settings, which a more generalised focus on multiple care settings, multiple diseases beyond just chronic disease or lack of focus on patient-reported outcomes may not achieve. There remains a need to assess the capabilities of CDSS in distinctive clinical professional areas and disease entities, particularly on patient outcomes. A recent review on EHR-embedded CDSS focused on process delivery (practitioner outcomes) and was not limited to primary care settings and chronic conditions. Despite obvious heterogeneity, clinically meaningful improvements in care processes were shown. However, it was unclear under what clinical circumstances these improvements could be replicated in every clinical context to affect clinical outcomes presumptively.

In this systematic review, patient outcomes refer to quantifiable clinical biomarkers such as glycated haemoglobin (HbA1c) and low-density lipoprotein cholesterol (LDL-C) levels, clinical outcomes such as mortality and morbidity, and patient-reported outcomes, such as health-related quality of life. To the best of our knowledge, and in the view of rapid upgrades in the world of CDSS, no review exists solely on the effect of CDSS embedded within EHRs on patient outcomes for patients with chronic disease managed in primary care. This review aims to fill this knowledge gap by collating all the available evidence on this classification of CDSS.

METHODS

Study design and eligibility criteria

A systematic review of the existing literature was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The research question, inclusion and exclusion criteria were defined using the PICO(S) framework. Nine common chronic diseases were selected as part of the inclusion criteria, following a review by Reynolds et al namely asthma, chronic obstructive pulmonary disease (COPD), heart failure, myocardial ischaemia, hypertension, type 2 diabetes mellitus (T2DM), hyperlipidaemia, arthritis and osteoporosis. Studies reporting on patient-related and clinical outcomes managed by primary care clinicians using CDSS-EHR compared with usual care were included. Studies involving participants ≥18 years of age, multidisciplinary (non-physician) system users, and other varieties of CDSS (not linked with EHR) were excluded. A detailed view of the criteria is provided in online supplemental table 1.

Figure 1 depicts an analytic framework of the intervention adapted from a framework published by Lobach et al. The framework provides a theoretical context for possible features that could underpin the success, or lack of success, of a complex intervention such as
implementing CDSS in a primary care setting. The framework guided the extraction of relevant data from studies to inform the narrative synthesis.

**Search strategy**
Electronic databases Medline, Embase, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL) and Health Management Information Consortium, and one clinical trial registry (clinicaltrials.gov), were searched from inception to 24 June 2020. Cochrane reviews were screened for relevant search terms and subject headings (MeSH) terms under the following categories ‘registries supported by CDSS’ AND ‘General Practice/Primary care’ OR each of the nine chronic diseases combined with AND ‘Asthma’, ‘heart failure/myocardial ischaemia’, ‘hypertension’, ‘diabetes mellitus’, ‘hyperlipidaemia’, ‘COPD’, ‘arthritis’, ‘osteoporosis’ (online supplemental tables 2 and 3). The search was limited to articles in English.

Terms for patient-reported outcome measures (PROM) were excluded. Existing PROM filters are not comprehensive, and the use of those filters in the search strategy could increase the risk of missing relevant studies. However, we manually screened papers to identify any ‘patient-reported outcomes’ measured in studies. PROM may be described in various ways; thus, attempting to list specific patient outcomes for each entity could introduce bias and lead to missing relevant studies. Previous systematic reviews around CDSS in primary care were also searched for potentially eligible studies.

**Study screening and selection**
Search results were exported to RefWorks, then screened using Covidence. After removal of duplicates, screening was conducted by two reviewers independently (MLEA and KID). Disagreements were resolved by consensus within the review group. After an initial screening of titles and abstracts, the full text of potentially relevant articles was assessed.

**Data extraction**
A data extraction form was adapted using the ‘Cochrane data collection form for intervention reviews: randomised
controlled trials (RCTs) and non-RCTs’ and aided by Lobach et al’s data abstraction guidance. The form was piloted and two reviewers (MLEA and KID) completed data extraction independently.

Quality assessment of individual studies
Risk of bias (RoB) was assessed using the Cochrane RoB tool, by two reviewers independently (MLEA and KID). The methodological RoB was assessed per the following elements in RCTs: selection bias, performance bias, detection bias, attrition bias, reporting bias and other biases.

Quasi-RCTs were reported as high risk for random sequence generation. Cluster RCTs were assessed for an additional element ‘selective recruitment of cluster participants’. All judgements were made with guidance from the Cochrane Handbook and the guidelines of the Cochrane Consumers and Communication Review Group.

Studies were considered as high risk if they scored ‘high’ or ‘unclear’ for either random sequence generation or allocation concealment, based on the rising evidence that these two elements are particularly significant sources of bias. A summary ‘RoB’ figure was generated for all risk assessments of elements with a narrative commentary for each study. Additionally, a detailed adapted table was generated to visualise subelements that fit under each element in the Cochrane RoB tool.

Quality assessment of outcomes
The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tool was used to assess the quality of outcomes from individual studies. The tool involves five elements: RoB, inconsistency, indirectness, imprecision and publication bias. The tool involves five elements: RoB, inconsistency, indirectness, imprecision and publication bias. The tool involves five elements: RoB, inconsistency, indirectness, imprecision and publication bias.

Data synthesis
Treatment effect was reported as ORs with 95% CIs and p values for dichotomous outcomes, where available. Continuous data were presented as mean differences with 95% CIs and p values.

Heterogeneity in the results was anticipated due to the wide spectrum of possible patient-related outcomes reported by the studies. Methodological heterogeneity was assessed using Cochrane RoB tool. Heterogeneity in included studies varied in terms of intervention components, population characteristics and outcome measurements; thus, conducting a meta-analysis was deemed not appropriate by the four-person author group.

Patient and public involvement
No patients were involved.

RESULTS
The search identified 5430 articles. Following removal of duplicates, 4498 articles remained for screening by title and abstract. Of these, 266 articles were selected for full-text review and 10 articles met the inclusion criteria. Among them, two articles were published protocols of included articles; thus, eight different studies were finally included. The detailed search results are presented in the PRISMA flowchart (figure 2).

Study characteristics
Characteristics of included studies are presented in table 1. Included studies comprised of patients in four disease areas: T2DM, asthma, hyperlipidaemia and hypertension. No studies on COPD, heart failure, myocardial ischaemia, arthritis and osteoporosis were identified. Six studies were cluster RCTs, one study was parallel-group RCT and one was quasi-RCT of stepped-wedge design. Most studies were conducted in the USA, and three studies took place in the UK, Spain and Belgium. Studies, both among the disease conditions and within each disease entity, differed appreciably in participant covariates, setting attributes and CDSS characteristics. These factors, compounded with the heterogeneity of the studies (as described in the Methods section) suggested that the reported outcomes were not fit for statistical pooling; hence, these factors justified not conducting a meta-analysis. Follow-up ranged from 6 months to 1.5 years. No study incorporated financial reimbursement before the implementation of interventions. Further details are presented in table 1.

CDSS characteristics
CDSS interventions were characterised based on their origin (commercial/local), delivery mode (user or system-initiated), user response (optional/mandatory), events (system functions), coupled EHR and auxiliary features (local clinician involvement in system development process, system accessibility to other team members, provision of performance feedback or coupled with user education). Additional information such as user training, user adherence and reported usability was recorded. Details are provided in table 2.

RoB and quality of the evidence
Online supplemental tables 4 and 5 provide risk assessment details. Overall, the included studies were impacted by RoB, mainly due to incomplete outcome data and uncertainty on blinding of outcome assessment and personnel. In most studies, it was unclear if outcome assessors were blinded. Additionally, blinding of physicians (CDSS users) was not possible across all studies, as they were the intended system users. Most studies reported substantial withdrawal rates due to poor follow-up. These limitations resulted in analysing subgroups (rather than the initially intended full cohorts) in some trials; hence, most studies were considered of high risk for incomplete outcome data.
Overall, quality of the evidence was rated as either moderate or low, with the most impact resulting from methodological risks of bias within studies. Online supplemental table 6 presents the quality of evidence evaluated using GRADE, with reasons stated for quality downgrading.

**Narrative synthesis**

**Diabetes mellitus**

Three studies assessed the effect of CDSS on clinical and patient-reported outcomes in patients with T2DM.\(^{38-40}\)

Gill et al retrieved slight, yet statistically significant, reduced HbA1c and LDL-C with the CDSS intervention compared with the control group, with a small between-group difference in HbA1c and LDL-C levels of 0.12% and 3.57 mg/dL, respectively (table 3).\(^{39}\) The reported reductions in HbA1c and LDL-C were clinically small; however, statistically, the intervention group had 52% higher odds of achieving personalised HbA1c levels, 56% higher odds of achieving HbA1c <7.0% and 34% higher odds of achieving an LDL-C <100 mg/dL compared with usual care patients over 1 year of follow-up. Nevertheless, compared with the control group, the intervention group had better-controlled baseline levels of HbA1c and LDL-C. The study by Gill et al involved system-initiated ‘push’ CDSS, which were integrated into EHRs already operating at participating practices. Reported limitations were of EHR-CDSS interoperability difficulties, which resulted in missing patient lab values.\(^{39}\) Other missing lab values also resulted from patients not returning for lab tests. In view of these limitations, a subset of randomised
Table 1: Characteristics of included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Study design</th>
<th>Duration</th>
<th>Sponsorship</th>
<th>Setting</th>
<th>Participants</th>
<th>Comparability</th>
<th>Condition identification from EHR</th>
<th>Participants</th>
<th>Age</th>
<th>Sex</th>
<th>Disease severity</th>
<th>Target outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schnipper et al (USA)</td>
<td>T2DM</td>
<td>RCT</td>
<td>6 months</td>
<td>The Agency for Healthcare Research and Quality</td>
<td>Partners HealthCare System, 10 practices at Brigham and Women's Hospital and Massachusetts General Hospital (academic)</td>
<td>NS 3431 patients</td>
<td>Comparable</td>
<td>IG: more females (statistically significant)</td>
<td>Control 3578 patients</td>
<td>IG: more females (statistically significant)</td>
<td>Patients meeting management goals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gill et al (USA)</td>
<td>T2DM</td>
<td>Cluster RCT</td>
<td>1 year</td>
<td>Primary care practices in Delaware and Maryland (community)</td>
<td>ICD-9CM EHR code</td>
<td>5 offices 60 PCPs 4484 patients Analysed (by subgroup): HbA1c: 2041 patients LDL-C: 2730 patients</td>
<td>5 offices 60 PCPs 1902 patients Analysed (by subgroup): HbA1c: 723 patients LDL-C: 931 patients</td>
<td>Comparable</td>
<td>Overall: 18–75 IG: older (statistically significant)</td>
<td>IG: better glycemic control, lower LDL-C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heselmans et al (Belgium)</td>
<td>T2DM</td>
<td>Cluster RCT</td>
<td>1 year</td>
<td>None</td>
<td>Belgian primary care practices using OneHealth EHR (community)</td>
<td>25 offices 60 PCPs Analysed: 14 offices 21 PCPs 1351 patients</td>
<td>Overall: ≥18 years IG: older (significant statistically)</td>
<td>CG: more males (statistically significant)</td>
<td>CG: more females (statistically significant)</td>
<td>HbA1c, LDL-C and BP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eccles et al (UK)</td>
<td>Asthma and angina</td>
<td>Cluster RCT</td>
<td>1 year</td>
<td>UK NHS research and development</td>
<td>General practices in north-east England (community)</td>
<td>Asthma or angina EHR code in prior 12 months</td>
<td>&gt;18 years; no details presented</td>
<td>NS</td>
<td>NS</td>
<td>Quality of life and condition-specific outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gill et al (US)</td>
<td>Hyperlipidaemia</td>
<td>Cluster RCT</td>
<td>1 year</td>
<td>None</td>
<td>MQIC of primary care practices across the country (academic and community)</td>
<td>Identified as having LDL levels recorded in EHR</td>
<td>Overall: 20–79 IG: younger</td>
<td>CG: more males (statistically significant)</td>
<td>CG: more females (statistically significant)</td>
<td>CG lower disease risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cobos et al (Spain)</td>
<td>Hyperlipidaemia</td>
<td>Cluster RCT</td>
<td>1 year</td>
<td>Novartis</td>
<td>General practices in Catalonia</td>
<td>Identified as having TC between 200 mg/dL and 400 mg/dL</td>
<td>20 offices 1046 patients</td>
<td>Overall: 18–94 years</td>
<td>CG: more females (statistically significant)</td>
<td>Comparable</td>
<td>Lipid values</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hicks et al (USA)</td>
<td>Hypertension</td>
<td>Cluster RCT</td>
<td>1.5 years</td>
<td>The Agency of Healthcare Research and Quality</td>
<td>Primary care practices affiliated with the Brigham and Women's Hospital</td>
<td>Identified as having two or more hypertension-related outpatient visits using EHR codes</td>
<td>7 offices 786 patients</td>
<td>Comparable</td>
<td>Comparably: &gt;20 IG: significantly higher % of patients with controlled BP at first visit</td>
<td>BP control</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopez et al (USA)</td>
<td>Hypertension</td>
<td>Non-RCT</td>
<td>1 year (2018)</td>
<td>Centre for Disease Control</td>
<td>Primary care practices in New York</td>
<td>Identified as having at least 1 ICD code for hypertension in EHR</td>
<td>7 offices 704 patients</td>
<td>18–85 years</td>
<td>NS</td>
<td>NS</td>
<td>BP control</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BP, blood pressure; CG, control group; EHR, electronic health record; HbA1c, glycated haemoglobin; ICD, International Classification of Diseases; ICD-9CM, International Classification of Primary Care (2nd edition); IG, intervention group; LDL-C, low-density lipoprotein cholesterol; MQIC, medical quality improvement consortium; NS, not stated; PCPs, primary care physicians; RCT, randomised controlled trial; TC, total cholesterol; T2DM, type 2 diabetes mellitus.
### Table 2  CDSS characteristics of interventions in included studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Origin</th>
<th>Delivery mode</th>
<th>User response</th>
<th>Events</th>
<th>Guidelines</th>
<th>Integrated EHR (name)</th>
<th>User training</th>
<th>User adherence</th>
<th>Usability</th>
<th>Auxiliary features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schnipper et al</td>
<td>Diabetes mellitus</td>
<td>Commercial</td>
<td>User-initiated</td>
<td>Optional</td>
<td>► Requests missing data. ► Alerts outputs of assessments of clinical care. ► Recommends orders for medication changes, laboratory studies, appointments and referrals</td>
<td>NS</td>
<td>Longitudinal medical record</td>
<td>Brief instructions at start monthly tips</td>
<td>Tracked use by clinician and sent customised emails</td>
<td>Used for 5.6% of eligible patients</td>
<td>Local user involvement in development process</td>
</tr>
<tr>
<td>Gill et al</td>
<td>Diabetes mellitus</td>
<td>Commercial</td>
<td>System-initiated</td>
<td>Optional</td>
<td>► Generates reports for patient-specific recommendations</td>
<td>American diabetes Association; European Association for the study of diabetes and ICD 9 coding</td>
<td>Multiple EHRs (previously employed)</td>
<td>Not provided</td>
<td>Qualitatively assessed through informal interviews</td>
<td>4/5 practices reported use</td>
<td>Recommendations also received by non-clinicians in care team</td>
</tr>
<tr>
<td>Heselmans et al</td>
<td>Diabetes mellitus</td>
<td>Commercial</td>
<td>User-initiated</td>
<td>Unclear</td>
<td>► Alerts for reminders, therapeutic suggestions and diagnosis-specific guideline links</td>
<td>Belgian and International Guidelines</td>
<td>HealthOne</td>
<td>Not provided</td>
<td>Not assessed</td>
<td>Not assessed</td>
<td>None</td>
</tr>
<tr>
<td>Eccles et al</td>
<td>Asthma and angina</td>
<td>Local</td>
<td>System-initiated (4 months) then altered to user-initiated</td>
<td>Optional</td>
<td>► Alerts management and prescription options and patient referrals</td>
<td>NS</td>
<td>AAH Meditel or EMIS systems</td>
<td>1-day training</td>
<td>Measured by a usage log</td>
<td>Median number of system interactions was 0</td>
<td>Education on system guidelines</td>
</tr>
<tr>
<td>Gill et al</td>
<td>Hyperlipidaemia</td>
<td>Commercial</td>
<td>System-initiated</td>
<td>Optional</td>
<td>► Alerts for overdue lipid tests. ► Alerts if patient has not met personalised lipid goals. ► Generates disease risk categories</td>
<td>ATP-III guidelines</td>
<td>Electronic medical record (centrivity)</td>
<td>1-year familiarity with system</td>
<td>Not measured</td>
<td>Not measured</td>
<td>Generates a list of patients who have not met lipid goals, outside office visits. Listed patients were sent a letter at the start and after 6 months of the study</td>
</tr>
<tr>
<td>Cobos et al</td>
<td>Hyperlipidaemia</td>
<td>Local</td>
<td>System-initiated</td>
<td>Optional</td>
<td>► Recommends therapeutic options. ► Recommends follow-ups. ► Recommends lab testing</td>
<td>ESCHM</td>
<td>Not specified</td>
<td>None</td>
<td>Monitored by CDSS</td>
<td>71%</td>
<td>None</td>
</tr>
<tr>
<td>Hicks et al (2008)</td>
<td>Hypertension</td>
<td>Local</td>
<td>System-initiated</td>
<td>Optional</td>
<td>Alerts for therapeutic options</td>
<td>AHA/ACC 2001 guidelines</td>
<td>Not specified</td>
<td>None</td>
<td>Assessed prescription of a recommended drug class within 1 week of clinic visit</td>
<td>NS</td>
<td>None</td>
</tr>
<tr>
<td>Lopez et al</td>
<td>Hypertension</td>
<td>Local</td>
<td>System-initiated</td>
<td>Optional</td>
<td>► Alerts for missing BP readings ► Alerts for therapeutic options</td>
<td>JNC- 7 guidelines</td>
<td>eClinicalWorks or MD Land</td>
<td>2-day training at start, 7 training sessions during second year and ad-hoc sessions as needed</td>
<td>Semi-structured interviews Reported all practices have used all CDSS components</td>
<td>Generates reports of patients by status to manage visits</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Outcome</th>
<th>Outcome definition</th>
<th>Absolute effects</th>
<th>Relative effects</th>
<th>Conclusions</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schnipper et al38</td>
<td>Diabetes</td>
<td>Odds of patients meeting management goals at the end compared with baseline</td>
<td>Targets undefined</td>
<td>Not reported</td>
<td>ITT: OR=1.02; 95% CI 0.99 to 1.04, p value not reported. PP: OR=1.16; 95% CI 1.08 to 1.25, p&lt;0.001</td>
<td>Intention-to-treat: non-significant odds of intervention patients meeting management goals compared with control patients at 6 months. Per Protocol: significant odds of intervention patients meeting management goals compared with control patients after follow-up period</td>
<td>Low</td>
</tr>
<tr>
<td>Gill et al (2017)39</td>
<td>Diabetes</td>
<td>Difference in A1c from baseline. Difference in LDL-C from baseline. Odds of patients achieving A1c and LDL-C goals</td>
<td>HbA1c goals:&lt;7% and &lt;7.5% in patients with microvascular complications. LDL-C goals:&lt;100 mg/dL</td>
<td>Difference in HbA1c from baseline: −0.08%±1.15%. Difference in LDL-C from baseline: −4.35±24.54 mg/dL</td>
<td>Adjusted HbA1c between-group difference (%): 0.12%, 95% CI 0.02 to 0.22; p=0.02. Adjusted LDL-C between-group difference (mg/dL): 3.57 mg/dL, 95% CI 1.80 to 5.34, p&lt;0.001. Odds of achieving personalised HbA1c goals: aOR=1.52, 95% CI 1.24 to 1.86, p&lt;0.001. Odds of achieving HbA1c &lt;7%: 1.56, 95% CI 1.27 to 1.91, p&lt;0.001. Odds of achieving HbA1c &lt;5%: 1.07, 95% CI 0.75 to 1.52, p=0.71. Odds of achieving LDL-C &lt;100 mg/dL: 1.34; 95% CI 1.11 to 1.61, p=0.002</td>
<td>Clinically small, yet statistically significant between-group reductions in HbA1c and LDL-C</td>
<td>Moderate</td>
</tr>
<tr>
<td>Heselmans et al40</td>
<td>Diabetes</td>
<td>Mean change of HbA1c. Mean change in BP. Mean change in LDL-C levels</td>
<td>NA</td>
<td>Not reported</td>
<td>Between-group difference in HbA1c means: −0.09%, 95% CI = −0.18 to 0.01; p=0.06. Between-group change difference in SBP: 0.13% (95% CI = −0.91 to 1.6, p=0.8; Between-group change difference in DBP: 0.12% (95% CI = −1.25 to 1.49, p=0.86. Between-group change difference in LDL-C: 1.76% (95% CI = −0.46 to 3.98, p=0.12</td>
<td>No significant changes in between-group means for HbA1c, BP or LDL-C</td>
<td>Moderate</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Study</th>
<th>Disease</th>
<th>Outcome</th>
<th>Outcome definition</th>
<th>Absolute effects</th>
<th>Relative effects</th>
<th>Conclusions</th>
<th>Quality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eccles et al&lt;sup&gt;41&lt;/sup&gt;</td>
<td>Asthma and angina</td>
<td>Patient-reported outcomes using generic measures: The Short Form 36 Health Survey Questionnaire (SF-36) and European Quality of Life Five Dimension (EQ-5D); Condition-specific measures: the Seattle Angina Questionnaire and the Newcastle Asthma Symptoms Questionnaire</td>
<td>Not reported</td>
<td></td>
<td>No effect on any patient outcome</td>
<td>Moderate</td>
<td></td>
</tr>
<tr>
<td>Gill et al&lt;sup&gt;42&lt;/sup&gt;</td>
<td>Hyperlipidaemia</td>
<td>The percentage of patients whose most recent LDL-C was at goal (%)</td>
<td>Defined by the ATP-III guidelines LDL goals: &lt;100 for high-risk, &lt;130 for moderate risk and &lt;160 for low risk patients</td>
<td>High risk: Baseline: 50% End: 53.3% P&lt;0.001 Moderate risk: Baseline: 64.1% End: 64.7% P&gt;0.1 Low risk: Baseline: 88.5% End: 87.9% P&lt;0.05</td>
<td>High risk: OR=1.17 (95% CI not reported), p&lt;0.05. Moderate risk: OR=0.29 (95% CI not reported), p&lt;0.05. Low risk: OR=1.74 (95% CI not reported), p&lt;0.05</td>
<td>A significant increase in proportion of patients attaining goals for all categories except the moderate-risk IG. No significant difference in improvement in any category compared with the CG</td>
<td>Low</td>
</tr>
<tr>
<td>Cobos et al&lt;sup&gt;43&lt;/sup&gt;</td>
<td>Hyperlipidaemia</td>
<td>Between-group differences in means of lipid values (mg/dL)</td>
<td>TC: 233.8 LDL-C: 149.2 HDL-C: 58.0 Triglycerides: 136.6</td>
<td>TC: 231.0 LDL-C: 146.5 HDL-C: 56.3 Triglycerides: 135.2</td>
<td>Difference, 95% CI, P value TC: −2.8 (−1.7 to −7.3), 0.218 LDL-C: −2.7 (−1.7 to −7.1), 0.227 HDL-C: −1.8 (−6.6 to −3.6), 0.142 Triglycerides: −1.4 (−8.3 to −11.2), 0.766</td>
<td>No impact detected on final lipid values</td>
<td>Moderate</td>
</tr>
<tr>
<td>Hicks et al&lt;sup&gt;44&lt;/sup&gt;</td>
<td>Hypertension</td>
<td>Absolute effects: Percentage of patients with controlled BP (%). Mean baseline and end SBP and DBP. Relative effects: Odds of BP control at outcome visit. Baseline and end difference in SBP and DBP</td>
<td>Controlled BP: &lt;130/80 mm Hg for patients with diabetes or renal failure &lt;140/90 mm Hg for other patients</td>
<td>48% baseline SBP: 136 mm Hg End SBP: 138 mm Hg Baseline DBP: 78 mm Hg End DBP: 77 mm Hg</td>
<td>OR: 0.96 Baseline between-group difference in SBP: 2 mm Hg, p=0.59 Baseline between-group difference in DBP: 2 mm Hg, p=0.67 End between-group difference in SBP: 0 mm Hg, p=0.67 End between-group difference DBP: 1 mm Hg, p=0.05</td>
<td>No differences between IGs in mean SBP or DBP readings at (end) outcome visits</td>
<td>Low</td>
</tr>
<tr>
<td>Lopez et al&lt;sup&gt;45&lt;/sup&gt;</td>
<td>Hypertension</td>
<td>Relative effects: odds of BP control post-intervention</td>
<td>Controlled BP: &lt;140/90 mm Hg for all patients</td>
<td>Not reported</td>
<td>OR=1.36, 95% CI 1.08 to 1.71, p=0.009</td>
<td>Significant odds of improvement of BP in the IG compared with usual care</td>
<td>Low</td>
</tr>
</tbody>
</table>

aOR, adjusted OR; ATP-III, Adult Treatment Panel-III; BP, blood pressure; CG, control group; DBP, diastolic blood pressure; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein cholesterol; IG, intervention group; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol.
patients without missing HbA1c and LDL-C values were analysed (table 3).

Schnipper et al (RCT) reported the odds of patients meeting management goals (table 3). 38 Intention-to-treat analysis showed non-significant changes in patients’ odds of meeting management goals; a per-protocol analysis, however, showed slightly significant odds of attaining management goals in the intervention group compared with the control group (table 3). Among the three studies, this intervention is the only one that involved user training (table 2). Auxiliary features also included feedback on performance and local user (physician) involvement in the CDSS development process; yet, system usability was reported to be used for only 5.6% of patients (table 2).

Heselmans et al (cluster RCT) reported non-significant between-group differences in HbA1c, LDL-C, diastolic blood pressure (DBP) and systolic blood pressure (SBP) (table 3). 40 Levels of HbA1c were relatively well controlled, with reasonable mean values for HbA1c in both groups at baseline, especially in the control group (table 1). 38 Subsequent analysis of a subgroup of 601 patients with HbA1c >7.0% retrieved a statistically significant between-group difference in HbA1c favouring the intervention, though not clinically relevant (~0.40% (95% CI ~0.70 to ~0.09)). The same analysis retrieved non-significant differences in LDL-C and BP. User adherence and usability were not measured.

In all three studies, there was no mention of the provision of reimbursement for the implementation of the CDSS. All CDSS were commercial, and user response to the system alerts was optional.

Asthma and angina
One study assessed the impact of CDSS on self-reported quality of life and condition-specific outcomes in patients with asthma and angina. 41 The angina intervention group acted as the control group for the asthma intervention group and vice versa (justified by authors to eliminate a possible Hawthorne effect in practitioner behaviour on the primary outcome). Questionnaires were administered in three rounds (a year before the intervention, beginning of the intervention and a year after the intervention), which showed non-significant differences in both intervention groups post-intervention (table 3). Completion of the three rounds of questionnaires occurred in 46% and 35% of patients with angina and asthma, respectively. The implemented CDSS were locally produced and embedded in two widely used health systems (table 2). The CDSS were modified 4 months into the study from system to user-initiated, as requested by participating physicians. User training was limited, and system usability was very low, measured using a log with a median of zero user-system interaction during most of the study (table 2).

Hyperlipidaemia
Two studies involved participants with hyperlipidaemia. 42 43 The study by Gill et al involved implementing a commercial CDSS in participating practices of one institution. 42 All patients enlisted under participating practices with recorded LDL-C values were enrolled. A high correlation in outcomes was found at baseline and end measurements, causing patients not meeting LDL-C levels after randomisation to be analysed only. The control group also had a lower risk of disease and was significantly younger. Patients were stratified into three guideline-based risk groups, and the percentage of patients reaching the predefined goals at baseline and end were recorded (table 1). All categories in the intervention and control groups showed a significant increase in the proportion of patients attaining lipid goals, except in the moderate-risk group. Calculated differences were not presented; however, p values of differences within the intervention and control groups suggested no significant improvement in any risk category.

In Cobos et al despite a usability of 71%, the intervention had no superior over usual care in terms of between-group differences in lipid values (table 3). 43 The study reported >25% patients lost to follow-up for clinic visits or LDL-C testing (table 1).

Hypertension
Two studies assessed the effect of CDSS on BP in hypertensive patients. 44 45 Both studies employed CDSS that were system-initiated with optional user responses (table 2).

Hicks et al reported no differences between intervention groups in BP control (table 3). 44 Differences in baseline and end SBP and DBP between groups were not significant. Nonetheless, the intervention group had a significantly higher percentage of patients with controlled BP (table 1). No user training was provided, and system usability was not measured (table 2). Less than 80% of recruited patients were followed-up due to withdrawals caused by the study’s inclusion criteria, which required patients to have a recorded ethnicity in the EHR. Subsequently, patients without BP recordings were considered uncontrolled. However, a subset analysis excluding these patients still retrieved a non-significant difference in BP values.

Lopez et al’s study was a quasi-RCT and reported significant odds of BP improvement in the intervention group compared with the control group (table 3). 45 Notably, extensive training was provided for participating clinicians compared with all other studies, and semi-structured interviews revealed that all practices appeared to use the system components (table 1).

DISCUSSION
Main findings
As primary care providers are increasingly required to monitor and manage chronic diseases, there is a need to assess the capabilities of CDSS on patient outcomes. This systematic review included the eight available studies on the effect of computerised, knowledge-based,
EHR-embedded CDSS on clinical and patient-reported outcomes. Several study designs were included in the eligibility criteria; however, studies fit for inclusion were trials, namely, RCTs, cluster RCTs and non-RCTs (table 1, online supplemental table 1). Two studies reported a statistically significant impact of CDSS on patient outcomes, with one reporting clinically small yet significant reductions in HbA1c and LDL-C and another reporting significant increases in the proportion of hypertensive patients who achieve goals, which may be clinically relevant. Another two studies reported statistically significant findings but in subgroup analyses. One study reported statistical significance in partial outcomes and three studies did not report any statistically significant impact of CDSS on outcomes at all. Overall, evidence was not conclusive to imply a differential effect, either positive or negative, of clinician use of CDSS on patient or clinical outcomes compared with usual care, mainly due to the quality of evidence impacted by the prominent RoB in the included studies. The systematic review also noted a limited availability of studies evaluating the CDSS of interest directed to clinicians in primary care for the management of the common chronic diseases. This is especially true for COPD, arthritis and osteoporosis, which were eligible conditions, yet no such studies were available.

Implications of the review
The systematic review infers the importance of considering how the interplay of factors such as the nature of a healthcare setting (academic and community) and CDSS interact with clinicians (or users per se). System-initiated CDSS seemed to have a better reflection on patient outcomes compared with user-initiated systems; however, this relationship was confounded by many factors such as poor process measures, namely, low system usability and EHR–CDSS interoperability difficulties. A common limitation reported across most studies was poor patient follow-up, which highlights the importance of patient behaviour as a confounding factor to the performance of CDSS interventions in clinical settings. Some interventions included helpful auxiliary features such as involvement of local physicians in CDSS development and feedback on performance; yet, these features did not seem to reflect positively on patient outcomes. Understanding user (clinician) experiences qualitatively in the context of using such CDSS to manage chronic diseases in primary care may be of benefit to inform on their practical use. This review assessed CDSS functionality when used by clinicians; however, CDSS accessibility to other members of a multidisciplinary team may have an added positive effect, which could translate into better patient outcomes. Multidisciplinary teams in primary care have been shown to aid successful implementation of CDSS by increasing adherence to CPGs and improving patient outcomes in the absence of CDSS. The healthcare setting and intervention implementation itself may dictate the success or failure of an intervention. Large academic care settings may be better equipped with IT and financial resources than community centres to ensure successful implementations of CDSS. Included studies revealed limitations due to poor implementation of the CDSS, namely, interoperability issues, lack of IT support, poor usability and lack of user training, which could have hindered the intervention from reflecting significant outcomes compared with usual care. Models have been offered to help explicate how structural elements of healthcare settings and various levels of healthcare organisations levelling up to the industry may influence clinician behaviour and uptake of health IT to influence patient outcomes. Finally, it is imperative to consider the effect of non-clinical factors such as patient behaviour outside clinic visits, their perceptions and adherence to clinical advice.

Comparison with previous reviews
Previous reviews of CDSS of multiple types have indicated impact on patient outcomes in some instances. A recent review showed that CDSS systems achieve small to moderate effects on processes of care; yet, the extent of translation to patient outcomes and under what clinical contexts and conditions this was achieved was not determined. Previous reviews were not limited to primary care settings and included various other CDSS, namely, paper-based, web-based, stand-alone electronic systems, and patient-directed systems that do not necessarily alert a clinician at the point of care. However, reviews assessing the impact of various types of CDSS on chronic disease patient outcomes in primary care identified inconclusive results, with a need to define more clearly the exact role of CDSS compared with usual care in subsequent studies. Reviews evaluating patient outcomes noted conceptual between-study heterogeneity, as this review did, especially when several diseases and clinical outcomes were considered. In terms of patient outcomes, CDSS seem to affect clinical outcomes for cardiovascular risk factors such as hyperlipidaemia and diabetes. Nevertheless, a much more recent review on the effect of CDSS on cardiovascular risks revealed no definitive clinical benefits after their implementation. On the other hand, the evidence is less robust for other non-cardiovascular risk-related chronic conditions such as cancer and other primary care sensitive cases (PCSCs) such as vaccination, which were not part of the eligibility criteria in this review.

A review of CDSS embedded within EHRs in all-purpose healthcare settings on overall mortality and morbidity suggested no effect of CDSS on mortality. However, it noted that potential benefits or risks would highly depend on setting and disease characteristics, which is an evident implication in this review. A review by Bryan et al. validated the use of CDSS in primary care to improve outcomes; however, they reported substantial variability in intervention effectiveness related to the type and implementation of the different types of CDSS. Additionally, other reviews incorporated studies that involved the use of CDSS by multidisciplinary care members,
reflecting positive clinical outcomes with shared decision-making.\textsuperscript{19,31,55}

Unanswered questions and future research
More research is needed to establish the effectiveness of EHR-embedded CDSS on clinical outcomes of patients with chronic diseases treated in primary care settings. Further studies involving patients with chronic diseases are needed for robust evidence. Moreover, it may not be reasonable to evaluate the intervention’s efficacy based on older studies, given the exponential growth and rapid advancements in the field of CDSS.\textsuperscript{56} Future research could include practitioner-related cost effectiveness and patient-related outcomes to present an ampler perspective on the effect of this type of CDSS to inform policy-making and clinicians. Other PCSCs can be studied for a broader scope, including cancer, mental health illnesses and preventive interventions such as vaccination.\textsuperscript{57} Research around prolonged evaluations of CDSS is needed. Longer-term studies may account for potential implementation barriers that could take place. Additionally, it would be beneficial to synthesise findings on the effect of this particular type of CDSS on patient outcomes, when operated within a multidisciplinary team of non-clinician providers. It is worth noting that patient outcomes are not always addressed efficiently in trials, among the reasons is the possibility of having subjective, composite or surrogate outcomes, which do not necessarily translate into real-life patient outcome improvements.\textsuperscript{58} Hence, including observational studies in updated reviews may be useful. Additionally, no studies of registries embedded with CDSS fit the eligibility criteria, suggesting a potentially greater inclination to embed CDSS with EHRs currently. There also seems to be a dearth of studies evaluating non-cardiovascular risk-related chronic diseases post-implementation of CDSS linked with EHRs, as no studies evaluating patients with COPD, osteoporosis and arthritis were eligible.

Strengths and limitations
This systematic review focuses on interventions involving a specific type of CDSS—those that are knowledge-based, coupled with EHR systems, that provide electronic alerts and are used by physicians in primary care to support chronic disease management. To the authors’ knowledge, no such review exists considering this combined focus and given the attention these systems are increasingly gaining in primary care settings.\textsuperscript{29} As an example of the novelty of this review, compared with previous reviews with the most similar focus to our own by Bryan and Boren,\textsuperscript{23} and Bright \textit{et al},\textsuperscript{19} this review included studies not featured in these previous reviews such as the studies by Schnipper \textit{et al},\textsuperscript{38} Gill \textit{et al},\textsuperscript{40} Heselmans \textit{et al} and Hicks \textit{et al}.\textsuperscript{39,44} Application of the eligibility criteria identified eight studies for inclusion, which may be a small number given the recent growth of interest in CDSS in healthcare settings.\textsuperscript{59} Nevertheless, piloting the electronic search strategy and supplementing it with hand searching of reference lists of previous reviews in the field permitted a sufficient level of confidence that all relevant articles, against the eligibility criteria, were included for synthesis. The review also contributes to the knowledge provided by a recent review that focuses on process outcomes.\textsuperscript{24}

Some limitations arose from methodological constraints. Studies were of an average of 1-year duration, which makes it difficult to deduce long-term effects on patient outcomes. Nine common chronic diseases were included in the syntax.\textsuperscript{28} However, there was an absence of eligible studies in five of them, which limited the number of studies for inclusion. Although a selection of nine chronic diseases was included in the syntax, these covered the most common chronic diseases, as done by Reynold \textit{et al}.	extsuperscript{29} The review could have covered other PCSCs for a broader scope, including cancer and mental health illnesses, per se. The included studies were also of low-to-moderate quality of evidence. Additionally, our review does not report on process outcomes. The decision to exclude process outcomes such as practitioner-related outcomes, namely, clinician adherence to CPGs was made to channel the research question to focus on where the most significant knowledge gap lies, as the effect of CDSS on patient outcomes remains largely uncertain.\textsuperscript{19–21,25,24} Nevertheless, capturing those outcomes would have provided a more comprehensive assessment on the effect of CDSS for the management of patients with chronic disease in primary care. The heterogeneity in study intervention components, participant covariates, setting attributes and CDSS characteristics rendered outcome pooling in a meta-analysis not suitable.

Conclusion
This systematic review aimed to assess the impact of CDSS integrated with EHRs on patient-reported and clinical outcomes of chronic disease patients in primary care settings. A definite conclusion on the intervention effect on outcomes could not be drawn due to between-study heterogeneity and methodological risks, reflecting an immature research area. Intervention characteristics and implementation approaches may have an impact on outcomes from CDSS use and we make reference to the literature in this area that may guide and help evaluate successful implementations of CDSS in practice. Further studies are needed to formulate more robust inferences and validate the intervention’s effect on patient outcomes. With the continuous rise in the prevalence of chronic diseases, it is essential to understand how enhancing primary care management using IT support could support improved outcomes. Practical applications of CDSS evaluations in the healthcare workflow and setting should be sustained to suitably determine the actual effectiveness of CDSS and support improved implementation efforts into practice. Strengthening the clinical benefit of CDSS and determining their cost

\textsuperscript{12}


BMJ Open: first published as 10.1136/bmjopen-2021-054659 on 22 December 2021; Downloaded from http://bmjopen.bmj.com/ on May 12, 2022 by guest. Protected by copyright.
effectiveness could inform policy-making of enhanced primary healthcare of chronic disease management.

Author affiliations
1 Self Care Academic Research Unit, Imperial College London, London, UK
2 Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, London, UK
3 Imperial Centre for Cardiovascular Disease Prevention (ICCP), Department of Primary Care and Public Health, School of Public Health, Imperial College London. London, United Kingdom, London, UK
4 Department of Medicine, Faculty of Medicine, University of Seville, Seville, Spain
5 Clinical Epidemiology and Vascular Risk, Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/Universidad de Sevilla/CSIC, Seville, Spain
6 Department of Primary Care Clinical Sciences, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
7 Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK

Acknowledgements
The authors would like to thank the library services team at Imperial College London. Special thanks to Rebecca Jones for her support in reviewing the search strategy. KID acknowledges support from a PhD studentship from the National Institute for Health Research (NIHR) under the Applied Health Research (AHRQ) programme for North West London, UK (the views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health). AJV-V acknowledges support from a fellowship from the ‘Programa Beatriz Galindo’ from the Ministry of Universities of Spain, and University of Seville, Spain.

Contributors
RI conceived the original study concept with input from NM. NM and AJV-V led the overall study design and supervised the subsequent steps of the study. MIAE and KID designed the search strategy with supervision from the other authors and conducted the literature search, data extraction and quality assessment of studies. MLEA wrote the first draft of the manuscript. All authors participated in the interpretation of data, have critically reviewed the manuscript and provided edits and comments, and approved its final submission. NM acts as the guarantor and RI and NM are joint principal/last authors.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
RI and NM are employees of Cerner UK, a health technology organisation. AJV-V reports past or current participation in investigator-initiated research grants to Imperial College London from Pfizer, Amgen, Sanofi, MSD, Daiichi Sankyo and Regeneron, honoraria for lectures from Amgen, Mylan and Acesa, and steering committee/consulting fees from Radcliffe Cardiology and Bayer, all outside the submitted work. KID reports past or current participation in investigator-initiated research grants to Imperial College London from Amgen, Sanofi, MSD, Daiichi Sankyo and Regeneron and consulting fees from Bayer, all outside the submitted work.

Patient consent for publication
Not applicable.

Ethics approval
This study does not involve human participants. The present work relied on already published aggregated data and ethics committee approval was unnecessary.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study. The present work relied on already published aggregated data.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Marie El Asmar http://orcid.org/0000-0002-8481-6431

REFERENCES
17 Aakhus JSA, Alison E, Sarah N. Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Informat Decision Making 2017;17:1–9.
27 Howard C. Subject and course guides: evidence based medicine: PICO. Available: https://researchguides.uic.edu/c.php?g=252338&p=384242
30 Data extraction forms. Available: https://dplp.cochrane.org/data-extraction-forms
35 Ryan R, Hill S, Frictor M, Cochrane consumers & communication group review study quality guide, guide for review authors on assessing study quality, 2013.
36 BMJ Best Practice. What is GRADE? Available: https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/
48 McClellan SR, Casalino LP, Shortell SM, et al. When does adoption of health information technology by physician practices lead to use by physicians within the practice? J Am Med Inform Assoc 2013;20:e26–32.